Shiraki, Masataka http://orcid.org/0000-0001-6599-6185
Kuroda, Tatsuhiko http://orcid.org/0000-0002-2261-309X
Takeuchi, Yasuhiro http://orcid.org/0000-0002-0847-5233
Sugimoto, Toshitsugu http://orcid.org/0000-0003-0627-1816
Tanaka, Satoshi http://orcid.org/0000-0001-8192-5125
Suzuki, Hiroaki http://orcid.org/0000-0001-8005-9659
Hiraishi, Kazuki http://orcid.org/0000-0002-9368-9614
Nakamura, Toshitaka
Clinical trials referenced in this document:
Documents that mention this clinical trial
Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study
https://doi.org/10.1007/s00223-021-00884-7
Funding for this research was provided by:
Asahi Kasei Pharma Corporation
Article History
Received: 12 April 2021
Accepted: 25 June 2021
First Online: 10 July 2021
Declarations
:
: Masataka Shiraki has received consulting fees from Asahi Kasei Pharma, MSD, and Teijin Pharma and lecture fees from Astellas Pharma, Chugai Pharmaceutical, Daiichi-Sankyo, Eisai, Eli Lilly Japan, Ono Pharmaceutical, and Pfizer. Yasuhiro Takeuchi has received research grants and/or consulting fees from Amgen K.K., Eli Lilly Japan, Chugai Pharmaceutical, Teijin Pharma, Asahi Kasei Pharma, and Daiichi-Sankyo. Toshitsugu Sugimoto has received research grants from Astellas Pharma, Eisai, Ono Pharmaceutical, Daiichi-Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan, and consulting and/or lecture fees from Asahi Kasei Pharma and Pfizer. Toshitaka Nakamura has received consulting fees from Asahi Kasei Pharma, Amgen, Chugai Pharmaceutical, Daiichi-Sankyo, Eli Lilly Japan, MSD, Taisho Toyama Pharmaceutical, and Teijin Pharma. Tatsuhiko Kuroda is an employee of Asahi Kasei Corporation. Satoshi Tanaka, Hiroaki Suzuki, and Kazuki Hiraishi are employees of Asahi Kasei Pharma Corporation.
: The study was conducted according to the ethical principles of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and other applicable laws and regulations. The protocol was reviewed and approved by the institutional review boards of the participating study sites.
: All patients provided written informed consent before the initiation of the study.
: All participants gave their written informed consent for the publication of the data in an anonymized form.